ArticleJournal for immunotherapy of cancer2021

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.

Nadine Aschmoneit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.